WOS: 000177706600005PubMed ID: 12217193Twenty-five patients were treated for osteosarcoma of the extremity at Ege University Hospital. Eight of them were metastatic. All patients received cisplatin, doxorubicin, ifosfamide, and methotrexate preoperatively. Twenty-three patients underwent surgery at around week 15 (11-18 weeks). All but one underwent limb-sparing surgery. While good responders continued to receive the same drugs, poor responders were given the same regimen before 1996, but high-dose ifosfamide alone after 1996. For all patients the projected event-free survival (EFS) rates were 63.5% at 2 years and 53% at 5 years. The projected overall survival (OS) rates were 72% at 2 years and 62% at 5 years. For nonmetastatic patients, 5-...
International audienceBACKGROUND:In most countries, reference chemotherapy for osteosarcoma is MAP r...
PURPOSE: To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 4...
none6Around 1148 patients with non-metastatic osteosarcoma of the extremity were treated in a single...
BACKGROUND: The objective of this report was to estimate long-term outcome and prognostic factors in...
The objective of this report was to estimate long-term outcome and prognostic factors in children an...
From January 1993 to March 1995, 162 patients with osteosarcoma of extremities were treated accordin...
COSS, the interdisciplinary Cooperative German-Austrian-Swiss Osteosarcoma Study Group, was founded ...
Background and Purpose: The superiority of changing postoperative chemotherapy of osteosarcoma based...
Background and purpose The Scandinavian Sarcoma Group (SSG) XIV protocol is based on experience from...
Purpose To explore the effect of high-dose ifosfamide in first-line treatment for patients <= 40 yea...
BACKGROUND: Based on the results of the ISG/OS-1 study, the MAP regimen (methotrexate [MTX], doxoru...
Background. Based on the results of the ISG/OS-1 study, the MAP regimen (methotrexate [MTX], doxorub...
Background: Effective adjuvant or neoadjuvant regimens of chemotherapy have dramatically improved th...
The results of 131 cases of classic non-metastatic osteosarcoma of the extremities treated with preo...
BACKGROUND. The objective of this study was to estimate the time to treatment failure and survival r...
International audienceBACKGROUND:In most countries, reference chemotherapy for osteosarcoma is MAP r...
PURPOSE: To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 4...
none6Around 1148 patients with non-metastatic osteosarcoma of the extremity were treated in a single...
BACKGROUND: The objective of this report was to estimate long-term outcome and prognostic factors in...
The objective of this report was to estimate long-term outcome and prognostic factors in children an...
From January 1993 to March 1995, 162 patients with osteosarcoma of extremities were treated accordin...
COSS, the interdisciplinary Cooperative German-Austrian-Swiss Osteosarcoma Study Group, was founded ...
Background and Purpose: The superiority of changing postoperative chemotherapy of osteosarcoma based...
Background and purpose The Scandinavian Sarcoma Group (SSG) XIV protocol is based on experience from...
Purpose To explore the effect of high-dose ifosfamide in first-line treatment for patients <= 40 yea...
BACKGROUND: Based on the results of the ISG/OS-1 study, the MAP regimen (methotrexate [MTX], doxoru...
Background. Based on the results of the ISG/OS-1 study, the MAP regimen (methotrexate [MTX], doxorub...
Background: Effective adjuvant or neoadjuvant regimens of chemotherapy have dramatically improved th...
The results of 131 cases of classic non-metastatic osteosarcoma of the extremities treated with preo...
BACKGROUND. The objective of this study was to estimate the time to treatment failure and survival r...
International audienceBACKGROUND:In most countries, reference chemotherapy for osteosarcoma is MAP r...
PURPOSE: To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 4...
none6Around 1148 patients with non-metastatic osteosarcoma of the extremity were treated in a single...